Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oncofid-s
- Development stage
- Preclinical
- Lead developer
- Fidia Farmaceutici
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intraperitoneal
01
Overview
ONCOFID-S is a **bioconjugate drug** consisting of SN-38 (the active metabolite of irinotecan) chemically linked to hyaluronan (hyaluronic acid). SN-38 is a topoisomerase I inhibitor with potent antitumor activity, but its clinical utility is limited by poor water solubility and toxicity. By conjugating SN-38 to hyaluronan, ONCOFID-S improves solubility and enables **CD44-mediated selective targeting** of tumor cells that overexpress the CD44 receptor, such as ovarian cancer cells. This targeted delivery system allows SN-38 to be released in the tumor microenvironment, inhibit topoisomerase I, induce DNA damage, and trigger apoptosis via caspase activation. The formulation is designed primarily for **intraperitoneal loco-regional treatment of ovarian cancer** and has shown enhanced activity and safety compared to CPT-11 (irinotecan) in preclinical models. ONCOFID-S has also shown antitumor activity in mouse models of colorectal peritoneal carcinomatosis[1][5].
- Brand names
- ONCOFID-S
- Other names
- ONCOFID-S
02
Targets
TOP1 (DNA Topoisomerase I)CD44 (CD44 antigen)
Beyond the preview
Go deeper on oncofid-s.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oncofid-s.